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Abstract
Clinical trials using somatic gene editing (e.g., CRISPR–Cas9) have started in Europe and the United States and may provide
safe and effective treatment and cure, not only for cancers but also for some monogenic conditions. In a workshop at the
2018 European Human Genetics Conference, the challenges of bringing somatic gene editing therapies to the clinic were
discussed. The regulatory process needs to be considered early in the clinical development pathway to produce the data
necessary to support the approval by the European Medicines Agency. The roles and responsibilities for geneticists may
include counselling to explain the treatment possibilities and safety interpretation.
Introduction
Monogenic conditions have traditionally been considered
incurable. Somatic gene therapy (SGT) and especially gene
editing (e.g., with clustered regularly interspaced short
palindromic repeats–CRISPR-associated 9 (CRISPR–
Cas9)) have generated new hope for improved treatment.
Indeed, SGT approaches are currently being tested and
some are offered to patients (Table 1). Especially for gene
editing, concerns still remain, for example, regarding
immunological and general safety as well as questions of
equity and economics.
During a workshop at the European Human Genetics
Conference 2018, we discussed how SGT may change the
face of medicine, especially for rare genetic diseases. We
discussed:
● The current state of science, especially for genetic
editing;
● The legal and regulatory challenges;
● Equity in access; and
● The potential role of geneticists.
Trials using somatic gene editing: the
current status
The treatment of genetic diseases using gene editing is
tempting in its simplicity: instead of treating the symptoms,
we could correct the cause. In comparison with traditional
gene therapy, the edited gene would be under normal
genetic regulators. SGT may also circumvent the ethical,
legal and safety problems of germline modiﬁcations. As of
August 2018, there are a handful of approved SGT products
on the market, none of which use gene editing.
The results from current clinical trials with zinc-ﬁnger
(ZFN) and transcription activator-like effector (TALE)
nucleases are promising but still only preliminary. For
example, CCR5 (and other) HIV receptor genes have been
removed from patient blood cells in vitro, resulting in lower
Human Immunodeﬁciency (HI) virus titre when the cells are
re-introduced in the patient [1]. In November 2017, the ﬁrst
in vivo gene editing clinical trial started for a metabolic
disease, mucopolysaccharidosis II, with ZFNs administered
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directly in the patient [2]. The ﬁrst CRISPR–Cas9 clinical
trials are underway in China for sporadic cancers and are
planned or started in the United States and the European
Union for haemoglobinopathies [2].
Importantly, it is likely that the fastest advancements
of SGT and information on safety will ﬁrst come from
the cancer ﬁeld, where the editing is often targeted to
immune cells for better therapeutic effect. This may not
directly tell us about the efﬁcacy of treating speciﬁc
inherited diseases, but will give valuable data about the
feasibility, treatment potential and risks of using SGT in
patients. The ﬁrst attempts and successes in genetic
editing of cells in inherited diseases will most likely
continue to be developed in the haematological and
metabolic ﬁelds.
What is needed to launch genome editing in
the clinic?
The development and sale of human medicinal products is,
rightly, one of the most highly regulated industries in the
world. As a general rule, medicinal products are required to
go through rigorous testing to establish the safety and
efﬁcacy of the product to the satisfaction of the regulatory
bodies charged with overseeing the industry. Gene therapy
medicinal products (GTMPs) are no exception to this
requirement, and present particular challenges for devel-
opers and regulators alike. They must balance the twin
imperatives of ensuring the safety, efﬁcacy and durability of
such treatments, while also providing an efﬁcient regulatory
service that facilitates access to potentially life-changing
and curative medicines for those in dire need of new
treatments.
In Europe, GTMPs must be approved centrally by the
European Medicines Agency (EMA) and fall within the
broader classiﬁcation of “advanced therapy medicinal pro-
ducts” (ATMPs). Along with GTMPs, there are two further
subclasses of ATMP: somatic cell therapy medicinal
products (sCTMPs) and tissue engineered products (TEPs).
The EMA has created a speciﬁc committee—the Committee
for Advanced Therapies (CAT)—to specialise in assessing
ATMPs and advising the Committee for Medicinal Products
for Human Use (CHMP) (and through them, ultimately
advise the European Commission) as to whether marketing
approval should be granted for such products [3].
The evidence that a developer of a therapy is required to
submit for consideration of a marketing approval takes the
form of a detailed data package comprising preclinical,
clinical, pharmacokinetic/pharmacodynamic and other data.
The clinical development pathway (traditionally divided
into preclinical, phase I, phase II and phase III studies) is
directed towards producing the data necessary to produceTa
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the technical package to support the approval of the
product.
However, as Scott Gottleib, FDA Commissioner, noted
in a keynote address to the Alliance for Regenerative
Medicine on 22 May 2018 [4], unlike traditional drug
review of small molecule and biologic therapies,
“where 80% of the review is focused on the clinical
portion of that process, and maybe 20% is focused on the
product issues…this general principal is almost com-
pletely inverted when it comes to cell and gene therapy”.
The establishment of clear clinical efﬁcacy at an early
stage even in small groups of patients, offset by the vastly
increased complexity of the product manufacturing and
quality control considerations, represents a real challenge to
the paradigms of the existing review pathway (in which
statistically signiﬁcant clinical efﬁcacy can be marginal, but
the product and quality issues are fairly straightforward).
Regulators have recognised this, and the Food and Drug
Administration (FDA) in the United States released a set of
six new draft guidelines on gene therapy on 11 July 2018
[5], shortly followed 2 days later by the EMA releasing a
substantial revision to its existing 2001 guidance on GTMPs
on 13 July 2018 [6]. It remains to be seen, however, how
these guidelines are translated into regulatory practice as the
new wave of gene therapy treatments progress through the
development and approval pathway.
Willingness to participate in clinical trials for
sickle cell disease
Approximately 5% of the world’s population carries variants
for haemoglobin disorders, mainly, sickle cell disease (SCD)
and thalassaemia [7]. Globally, 300,000–400,000 babies with
SCD are born each year, adding up to 14,242,000 affected
births between 2010 and 2050 [8]. Migration has increased
the number of individuals living with SCD in Northern Eur-
ope and the United States. While SCD was identiﬁed over a
100 years ago, limited treatments are available worldwide. A
need for improved health care is recognised for this chronic
disease with severe health complications and life expectancy
reduced on average by 30 years [9].
SCD is caused by a single point mutation in the sixth
codon of the beta-haemoglobin subunit. The molecular
mechanism of SCD has been identiﬁed as a potential target
for somatic gene editing. Two approaches to reduce the
burden and/or cure SCD using gene editing are currently
being investigated: correcting the beta-globin point mutation
[10] and targeting the BCL11A gene for foetal haemoglobin
reinduction [11], leading to higher levels of foetal hae-
moglobin and reduced disease severity. In January 2018,
National Institutes of Health (NIH) in the United States
launched a Somatic Cell Genome Editing program to develop
quality tools to perform effective and safe somatic genome
editing in human patients. These research tools will be made
widely available to the research community to reduce the time
and cost required to develop new therapies [12].
On 31 August 2018, the ﬁrst CRISPR clinical trial for β-
thalassaemia backed by two US companies was launched in
Regensburg, Germany [13]. On 13 September 2018, the US
National Heart, Lung, and Blood Institute at the NIH
announced the Cure Sickle Cell Initiative to support research
in SGT [14]. During the ESHG workshop, Vence Bon-
ham (see author list) reported on community-engaged
research to inform regulators, biotech companies and
researchers of the perspectives of the US sickle cell disease
community regarding their willingness to participate in
clinical trials and their views of the potential that gene
editing can be a curative treatment. Bonham reported that a
major concern is whether the SCD patient population will
have equitable access to SGT as a treatment option in clin-
ical care. The US NIH is taking an important step to make
the promise of a cure for this debilitating disease a reality.
Will geneticists move to treatment?
In the translation process of new technologies from the research
to the clinical context, the question of which stakeholder group
(s) will take on which roles and responsibilities must be
addressed in order to ensure a responsible offer of services. In
practice, relevant and pressing questions for somatic gene
editing include: Who will be the healthcare professionals
involved in the offer of SGT? In particular, given the (histor-
ical) central role clinical geneticists have played in diagnosing
genetic disease, we are particularly interested in the question:
what role, if any, will or should clinical geneticists play in the
offer of such treatments? If the assessment of safety of SGT
includes whole genome sequencing and analysis, will clinical
geneticists be involved in the interpretation and communica-
tion? As of now, very little guidance can be found in the
academic literature or in policy documents to answer these
questions. Roles and responsibilities of clinical geneticists and
genetic counsellors do not exclude treatment activities. They
could include counselling for SGT or helping to establish
adequate ethical frameworks. Furthermore, genetics labora-
tories may also assume responsibility to search for off-target
events for SGT services.
Conclusion
Clinical trials for somatic cell gene editing are currently
underway. While preliminary results are promising,
486 M. C. Cornel et al.
questions about safety, equity and responsible use in vul-
nerable populations remain. Furthermore, the regulatory
pathway leading to the development and approval of such
novel GTMPs appears difﬁcult to navigate. For clinical
geneticists there is an apparent opportunity.
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